Novo Nordisk's Ozempic and Wegovy have transformed from diabetes treatments to weight-loss phenomena, driving the company's revenue to unprecedented heights, with a projected DKK 232 billion in 2023. However, soaring demand has led to shortages, impacting diabetes patients and prompting the company to halt insulin pen distribution in some regions. As Novo Nordisk prepares to launch CagriSema, the global obesity market is expected to reach $37.06 billion by 2031, with GLP-1 receptor agonists dominating.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
